Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07221656

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.

Conditions

Interventions

TypeNameDescription
OTHERNon-Interventional StudyNon-interventional study

Timeline

Start date
2027-02-01
Primary completion
2028-12-31
Completion
2028-12-31
First posted
2025-10-28
Last updated
2026-04-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07221656. Inclusion in this directory is not an endorsement.

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (NCT07221656) · Clinical Trials Directory